BPG is committed to discovery and dissemination of knowledge
Review
Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 125273
Published online Nov 15, 2026. doi: 10.4251/wjgo.125273
Table 3 Main drugs used in the treatment of ulcerative colitis: Doses, mechanisms of action, and therapeutic response
Treatment
Dose scheme
Mechanism
Response
Ref.
5-ASAMesalazineInduction: 2.4-4.8 g/dayAnti-inflammatory by activating PPAR-y receptorsUC: Clinical and endoscopic remission[10,89,167,168]
Maintenance: 1.5-2.0 g/dayCD: Poor response
GlucocorticoidsBetamethasoneInduction: 5 mg/dayImmunosuppressors by reduced expression of IL-1, IL-1β and IL-8, TGF-β3 and IL-10UC: Clinical and endoscopic remission[167,169,170]
Budesonide MMXInduction and maintenance: 9 mg/day
HydrocortisoneInduction: 356 mg/dayCD: Clinical remission
PrednisoloneInduction: ≥ 30 mg/day
ThiopurinesAzathioprineInduction and maintenance: 1.5 to 2.5 mg/kg/dayImmunosupressor. Targets Rac1 activation and inhibits gut T cellsUC: Poor response in active disease. Used for remission maintenance[171-174]
CD: Clinical remission
6-mercaptopurineInduction and maintenance: 1-1.5 mg/kg/dayImmunosuppressor. Inhibits purine synthesisUC: Remission maintenance[175,176]
CD: Clinical remission or significant improvement
MethotrexateInduction and maintenance: 25 mg/weekImmunosupressor inhibits purine synthesisUC: Poor response[177-179]
Decrease in production of cytokines and eicosanoidsCD: Clinical remission and maintenance


Write to the Help Desk